Dyno Therapeutics launches with two deals, potentially worth $2 billion

11 May 2020

Cambridge, Massachusetts-based biotech Dyno Therapeutics has emerged from stealth with two strategic collaborations to develop improved gene therapies with AAV vectors based on AI (artificial intelligence) technology.

Dyno was spun out of the lab of Professor George Church of Harvard and formed in late 2018 with a $9 million financing co-led by Polaris Partners and CRV not previously announced.

The company did not disclose much by way of financial details, but said if everything proceeds on plan, the deals it has struck to date could collectively bring the company more than $2 billion.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK